Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification-Reference-Cited by-同舟云学术

Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification

Published:2019-09-02 Issue:8 Volume:11 Page:1479-1491
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Jin Weixin¹^ORCID,Xing Zizhuo¹,Song Yuanli¹^ORCID,Huang Chao¹^ORCID,Xu Xuankuo¹^ORCID,Ghose Sanchayita¹,Li Zheng Jian¹^ORCID

Affiliation:

1. Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2019.1658493

Reference65 articles.

1. The therapeutic monoclonal antibody market

2. Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy

3. Bispecific antibody based therapeutics: Strengths and challenges

4. Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/-mice

5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin Q5a(R1) [Internet]. 1999.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing monoclonal antibody stability during protein a chromatography using 2-methyl imidazolium dihydrogen phosphate;Journal of Chromatography A;2024-09

2. Modeling scalability of impurity precipitation in downstream biomanufacturing;Biotechnology Progress;2024-03-27

3. Acidic pH or salt treatment can convert soluble antibody aggregates in culture harvest into monomers and improve Protein A chromatography step yield;Protein Expression and Purification;2024-03

4. Stability analysis of monoclonal antibodies;Therapeutic Monoclonal Antibodies - From Lot Release to Stability Testing;2024

5. Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume;mAbs;2023-11-27